Priority 9 from the Sight Loss and Vision PSP Age Related Macular Degeneration

UNCERTAINTY: Can dietary factors, nutritional supplements, complementary therapies or lifestyle changes prevent or slow the progression of AMD? (JLA PSP Priority 9)

Overall ranking 9
JLA question ID 0014a/9
Explanatory note Reliable up-to-date systematic reviews revealed important continuing uncertainties about treatment effects at the time of the PSP
Evidence

Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for preventing age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 6. Art. No.: CD000253. DOI: 10.1002/14651858.CD000253.pub3.

Evans JR, Lawrenson JG. Antioxidant vitamin and mineral supplements for slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD000254. DOI: 10.1002/14651858.CD000254.pub3

Lawrenson JG, Evans JR. Omega 3 fatty acids for preventing or slowing the progression of age-related macular degeneration. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD010015. DOI: 10.1002/14651858.CD010015.pub2

Evans JR. Ginkgo biloba extract for age-related macular degeneration. Cochrane Database of Systematic Reviews 2013, Issue 1. Art. No.: CD001775. DOI: 10.1002/14651858.CD001775.pub2.
Health Research Classification System category Eye
Extra information provided by this PSP
Original uncertainty examples This is an indicative uncertainty and was submitted twice, and the following submissions were merged to form this uncertainty: Which supplements can improve macular health?
Systematic reviews that need updating or extending None identified
Systematic reviews in preparation (at time of PSP) None identified
Ongoing controlled trials

Intervention trial in early age-related macular degeneration I-TEAM NCT01694680

Walnuts and Healthy Aging WAHA NCT01634841

Effect of saffron supplementation on macular cone-mediated function in Age-related macular degeneration safAMD NCT00951288
Submitted by Carers
Outcomes to be measured Change in symptoms; adverse effects or complications; acceptability to the patient; and cost
PSP information
PSP unique ID 0014a
PSP name Sight Loss and Vision - Age Related Macular Degeneration
Total number of uncertainties identified by this PSP. 113  (To see a full list of all uncertainties identified, please see the detailed spreadsheet held on the JLA website)
Date of priority setting workshop April and May 2013